Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).
Janžič U, Turnšek N, Dediu M, Donev IS, Lupu R, Teodorescu G, Ciuleanu TE, Pluzanski A. Janžič U, et al. Among authors: donev is. Curr Oncol. 2022 Aug 17;29(8):5833-5845. doi: 10.3390/curroncol29080460. Curr Oncol. 2022. PMID: 36005198 Free PMC article.
Impact of travel burden on clinical outcomes in lung cancer.
Stoyanov DS, Conev NV, Donev IS, Tonev ID, Panayotova TV, Dimitrova-Gospodinova EG. Stoyanov DS, et al. Among authors: donev is. Support Care Cancer. 2022 Jun;30(6):5381-5387. doi: 10.1007/s00520-022-06978-8. Epub 2022 Mar 15. Support Care Cancer. 2022. PMID: 35288785
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT).
Addeo A, Hochmair M, Janzic U, Dudnik E, Charpidou A, Płużański A, Ciuleanu T, Donev IS, Elbaz J, Aarøe J, Ott R, Peled N. Addeo A, et al. Among authors: donev is. Ther Adv Med Oncol. 2021 Nov 29;13:17588359211059874. doi: 10.1177/17588359211059874. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 35173817 Free PMC article.
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
Petrova MP, Eneva MI, Arabadjiev JI, Conev NV, Dimitrova EG, Koynov KD, Karanikolova TS, Valev SS, Gencheva RB, Zhbantov GA, Ivanova AI, Sarbianova II, Timcheva CV, Donev IS. Petrova MP, et al. Among authors: donev is. Biosci Trends. 2020 Mar 16;14(1):48-55. doi: 10.5582/bst.2019.01279. Epub 2020 Feb 4. Biosci Trends. 2020. PMID: 32023563 Free article.
Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer.
Petrova MP, Donev IS, Radanova MA, Eneva MI, Dimitrova EG, Valchev GN, Minchev VT, Taushanova MS, Boneva MV, Karanikolova TS, Gencheva RB, Zhbantov GA, Ivanova AI, Timcheva CV, P Pavlov B, Megdanova VG, Robev BS, Conev NV. Petrova MP, et al. Among authors: donev is. Clin Exp Immunol. 2020 Dec;202(3):353-362. doi: 10.1111/cei.13505. Epub 2020 Aug 26. Clin Exp Immunol. 2020. PMID: 32757277 Free PMC article.
24 results